You can access the original SEC filing by clicking here.

Page 1 of 3 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Novelion Therapeutics Inc. |
(Name of Issuer) |
Common Stock, without par valuse |
(Title of Class of Securities) |
67001K103 |
(CUSIP Number) |
Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 With a copy to: Russell Leaf Willkie Farr & Gallagher LLP 787 Seventh Avenue New York, New York 10019 212-728-8000 |
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
August 1, 2017 |
(Date of Event which Requires Filing of this Statement) |